Actively Recruiting
Factors Associated With Mortality in Streptococcal Anginosus Bacteremia
Led by University Hospital, Strasbourg, France · Updated on 2026-01-15
400
Participants Needed
1
Research Sites
1 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating factors linked to mortality in infections caused by Streptococcal anginosus group bacteria, including S. constellatus, S. anginosus, and S. intermedius. These infections are known for their severity, high mortality rates estimated around 15%, and frequent infectious complications. The study aims to better understand what contributes to death in patients with these bloodstream infections. This is an observational study that looks at patients hospitalized with confirmed Streptococcal anginosus bacteremia. There are no treatments or interventions assigned by the study. Instead, researchers will collect and analyze data from patients who had positive blood cultures for these bacteria during the study period from January 1, 2019, through December 31, 2024. Participants will be adults 18 years or older who were hospitalized in participating centers and had at least one positive blood culture for the target bacteria. The main outcome measured is the 28-day in-hospital mortality following infection. The study will review medical records and laboratory results to identify factors associated with mortality. The research is sponsored by the University Hospital, Strasbourg, France, and the study is planned to end in March 2027.
CONDITIONS
Brief Title
Factors Associated With Mortality in Streptococcal Anginosus Bacteremia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Hospitalized between January 1, 2019, and December 31, 2024, in a participating center
- At least one positive blood culture for Streptococcus anginosus, Streptococcus constellatus, or Streptococcus intermedius during the study period
You will not qualify if you...
- Refusal to participate in the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 28 days
Participants who undergo routine care are observed for 28 days following their streptococcal infection to assess mortality outcomes.
Follow-up during hospitalization as per routine care
Trial Site Locations
Total: 1 location
1
Centre de référence des maladies vectorielles à tiques, CNR Borrelia - CHU de Strasbourg - France
Strasbourg, France, 67091
Actively Recruiting
Research Team
V
Victor GERBER, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here